The latest data from Symphony Health Solutions, released today, indicates that the Zubsolv market share (4w rolling average) were more or less unchanged in April compared to previous month at 5.7% (quantity) and of 5.2 (prescriptions). The prescription category (buprenorphine/naloxone) showed a y/y growth rate (4w rolling average) of 10.2% (quantity) and of 10.2% (prescriptions) in April.